KDR and cancer: It has been reported that TP53 has a close connection with VEGFA in cancer researches, for example, TP53 mutations are a marker of increased VEGF expression, and can predict sensitivity to VEGF/VEGFR inhibitors in cancer treatment (Wheler et al., 2016; Li et al., 2020).